Recursion Pharmaceuticals is trading 8.12% lower at $3.56, with no new November 5 company announcement identified that clearly explains the drop.
- A director’s reported sale of 40,000 shares was made under a pre-arranged trading plan; its role in today’s move is unclear.
- The S&P 500 was down 1.33% and Nasdaq down 2.45%, while biotech rose 2.05%.
- The recent earnings update was positive on revenue and cash runway, not an obvious explanation for the decline.